Antimicrobial control programs are widely used to decrease drug expenditures, but effects on antimicrobial resistance and outcomes for patients are unknown. When a requirement for prior authorization for selected parenteral antimicrobial agents was initiated at our urban, county teaching hospital, total parenteral antimicrobial expenditures decreased by 32%. Susceptibilities to all b-lactam and quinolone antibiotics increased, with dramatic increased susceptibilities in isolates recovered in intensive care units, increased susceptibilities in isolates recovered in other inpatient sites, and little change in susceptibilities in isolates recovered in outpatient sites despite no change in infection control practices. For patients with bacteremia due to gram-negative organisms, overall survival did not change with restrictions. No differences occurred in the median time from initial positive blood culture to receipt of an appropriate antibiotic or in the median time from positive blood culture to discharge from the hospital. Thus, requiring preapproval for selected parenteral agents can decrease antimicrobial expenditures and improve susceptibilities to antibiotics without compromising patient outcomes or length of hospital stay.
Control of antimicrobial use is a common target for manageAntimicrobial restriction policies have proved unpopular in spite of reductions in drug expenditures [1, 2] . Furthermore, ment of medical costs. Twenty-five percent to 30% of inpatients receive antibiotic therapy, which accounts for up to one-half the impact on overall health care costs is unknown. The acquisition cost of antimicrobial agents represents a large portion of of total drug expenditures [1 -3] . Antibiotics are frequently misused and overused [1 -5] . McGowan and Finland [6] first pharmacy budgets but only a small portion of medical expenditures [2] . If patient outcomes were adversely affected, restricreported that requiring justification for antimicrobials significantly decreased antibiotic expenditures. By the early 1980s, tions might actually increase total costs by prolonging hospitalization and increasing other clinical expenditures [24] . restriction policies for use of selected expensive antimicrobials had been adopted by most teaching hospitals [7] . These policies
We initiated a prior-authorization requirement for selected parenteral antimicrobial agents at our urban, county teaching have been associated with dramatic decreases in total antibiotic expenditures [3, 6, 8 -13 ], but the effects on outcomes for hospital in 1994. This requirement provided the opportunity to assess the impact of restrictions on antimicrobial expenditures, patients are less clear.
susceptibilities, and clinical outcomes. See editorial response by Kunin on pages 240 -1.
Methods
Antibiotic resistance is thought to result primarily from antibiotic use [14 -19] , and antibiotic control programs have been Ben Taub General Hospital is a 575-bed urban teaching proposed as a means of minimizing resistance [15, 20] . The hospital, the largest of three county hospitals in Houston. The degree to which these programs can influence the prevalence medical staff consists of faculty members of Baylor College of resistance is unknown [15] . For example, decreased use of of Medicine. Physician orders are written by house officers broad-spectrum antibiotics has been associated temporally with who rotate between Baylor College of Medicine -affiliated hosdecreased antibiotic resistance [21 -23] , but confounding facpitals. tors such as infection control efforts were not addressed in During early 1993, an epidemic of bacteremia due to Acinetmany previous reports [15] .
obacter sensitive only to imipenem was noted in the surgical intensive care unit (ICU). Infection control measures instituted to control this epidemic included isolation and grouping of patients (during much of 1993), an intensive educational pro-rization for selected antibiotics was introduced as a means of was sent and the time that the specimen arrived in the laboratory were recorded. controlling antimicrobial resistance and expenditures.
Implementation. Enforcement of the prior-authorization reWe studied the following three indicators of clinical outcome: survival, time to receipt of an appropriate antibiotic, and quirement began on 1 January 1994. A detailed account of implementation has been previously published [25] . Briefly, time to discharge after the first positive blood culture. Patients who survived for 30 days from the date of the first positive orders for intravenous amikacin, ceftazidime, ciprofloxacin, fluconazole, ofloxacin, and ticarcillin/clavulanate were not honblood culture or who were discharged alive before 30 days were considered survivors. The length of stay from the first ored without prior verbal authorization from the infectious diseases faculty. During the first 6 months, modifications included positive blood culture to hospital discharge or to ICU discharge was recorded for all survivors. The time from receipt of the removal of all restrictions on oral agents, addition of piperacillin/tazobactam to the formulary as an agent requiring prior first positive blood culture in the laboratory to receipt of the first dose of an appropriate antibiotic was noted. Antibiotics authorization, and addition of aztreonam to the list of agents for which preapproval was required. Control measures for vanwere defined as appropriate if the isolate was susceptible in vitro to at least one prescribed antibiotic, in keeping with the comycin were instituted after the period examined in this study. For adult medical/surgical inpatients, faculty of the Infectious guidelines of the Infectious Diseases Society of America [26] . Patients were stratified by using a modification of the simpliDiseases Service, Department of Medicine, were available 24 hours a day to provide antibiotic approval. Physicians were fied acute physiology score II (SAPS II) [27] . Data for calculating a Glascow coma score were not consistently available retrorequired to contact the infectious diseases attending physician via a dedicated pager to obtain approval before administration spectively; therefore, the SAPS II was modified to exclude the Glascow coma score. of any restricted antibiotic. In most cases, approval was granted, and this information was conveyed to the pharmacy by the Statistical analysis. Data were analyzed using the STATA software package (Computer Resource Center, Santa Monica, infectious diseases attending physician by a telephone call.
Expenditures and antimicrobial susceptibilities. Records CA). Monthly antimicrobial expenditures were compared by a paired two-tailed t test with use of P £ .05 as the level of of monthly antimicrobial expenditures were obtained from the hospital purchasing department. All antibiotic expenditures significance. Proportions were analyzed by the x 2 or Fisher's exact test with use of P £ .01 as the level of significance for were recorded at cost to the pharmacy (rather than charges). Data were examined in detail for the July -December period the sensitivity studies and P £ .05 for baseline characteristics and survival. Continuous variables (e.g., time to discharge and in 1993 and 1994 including cost for each antibiotic and number of doses administered. These periods were selected since there time to receipt of an appropriate antibiotic) were analyzed by a two-tailed Wilcoxon rank-sum test with use of P £ .05 as the were no major changes in cost per dose for drugs (with the exception of a 40% reduction in amikacin costs).
level of significance. Survival and time from positive blood culture to discharge for survivors were analyzed by using multiBacterial susceptibilities were determined by using the WAlkAway-96 system (Dade International, Dade MicroScan, ple logistic regression and Cox proportional hazard models, respectively; all variables were analyzed by univariate analysis and West Sacramento, CA), and the results were interpreted according to the guidelines of the National Committee for Clinical variables with P £ . 25 NOTE. Before Å the 6-month period immediately before implementation of the prior-authorization requirement; after Å the same 6-month period after full implementation of the prior-authorization requirement.
* Excludes tetracyclines, chloramphenicol, erythromycin, antituberculous agents, and other infrequently used antibiotics (total expenditures for all of these other agents were õ$1,000 per month).
† P õ .01. ‡ P õ .05.
$41,576. Adjusting for changes in occupancy, the reduction tively, to $2,359,177 and $1,806,359 in 1994 and 1995, respectively. Antibiotic costs per patient-day went from $16.7 and was $584.14 per 100 patient-days (66%).
Use of nonrestricted agents increased, with monthly expendi-$18.0 in 1992 and 1993, respectively, to $14.4 and $12.9 in 1994 and 1995, respectively. tures rising from $84,004 to $105,367; there were significantly increased expenditures for ceftriaxone, cefotetan, and tobraAntimicrobial susceptibility patterns. Susceptibilities to all b-lactam and quinolone antibiotics increased (tables 2 and 3). mycin whether analysis was based on cost or on doses administered. Adjusting for occupancy, the increase was $195.26 per Susceptibilities to both restricted and unrestricted agents increased, with more dramatic increased susceptibilities in iso-100 patient-days (34%). Expenditures for parenteral fluconazole decreased 53%. Similarly, expenditures for amphotericin lates recovered in ICUs than in other venues. For example, the percentage of Pseudomonas aeruginosa susceptible to imi-B, although not restricted, decreased 38%. The overall decrease in expenditures for parenteral antifungals was $4,563 per penem increased from 65% to 83% for isolates recovered in ICUs, from 83% to 95% for isolates recovered in other inpatient month. Adjusting for changes in occupancy, the decrease was $28.61 per 100 patient-days (43%). Overall, expenditures for settings, and from 86% to 88% for isolates recovered in outpatient settings. The percentage of P. aeruginosa isolates recovparenteral antimicrobial agents were $431,548 (32%) lower for the 6-month period in 1994 than for that in 1993. The decrease ered in inpatient wards that were susceptible to tobramycin decreased significantly (from 97% to 92%), but no other cliniin expenditures was primarily the result of a shift from more expensive agents (e.g., ceftazidime, aztreonam, ticarcillin/clacally significant decreasing of susceptibilities was noted.
Outcomes for patients with bacteremia due to gram-negative vulanate, amikacin, and intravenous fluconzole) to less expensive agents (e.g., ceftriaxone, cefotetan, tobramycin, and oral organisms. One hundred forty-one episodes of bacteremia in 137 patients occurred from July through December 1993 fluconazole) rather than a reduction in usage.
Total Outpatient  4  20  50  80  100  100  25  65  50  75  50  85  50  65  Inpatient  27  29  37  59  96  97  22  38  33  62  52  72  52  52  ICU  40  33  13  42*  98  100  5  24  8  33*  50  67  20  33 NOTE. Before Å the 12-month period immediately before implementation of the prior-authorization requirement; after Å a 12-month period after full implementation of the prior-authorization requirement; ICU Å intensive care unit.
* Increases were statistically significant (P £ .01).
records were unavailable were excluded from subsequent 119), respectively; survival rates associated with nosocomial bacteremia were 72.7% (32 of 44) and 70.9% (39 of 55), reanalysis.
Patients' mean age, race, sex, and mean modified SAPS II spectively, and survival rates associated with nosocomial bacteremia originating in the ICU were 66.7% (22 of 33) and were similar for both years (table 4) . By univariate analysis, more of the cases of bacteremia originated in the hospital (noso-64.1% (25 of 39), respectively. Trends suggested that the survival rates associated with baccomial), on the surgical ward, and in the ICUs in 1993, but these differences were not statistically significant by multivariteremia due to Pseudomonas and Enterobacter before restrictions and with infections due to Klebsiella and Acinetobacter ate analysis. The causes of bacteremia due to gram-negative bacilli also were similar for both years ( NOTE. Before Å the 12-month period immediately before implementation of the prior-authorization requirement; after Å a 12-month period after full implementation of the prior-authorization requirement; ICU Å intensive care unit; NA Å not applicable.
* Increases or decreases were statistically significant (P £ .01).
regression. Antibiotic restrictions were not a statistically sigexpensive agents. This requirement led to an estimated annual reduction in pharmacy expenditures for antimicrobials of nificant factor in either comparison.
No significant differences were identified between years in $863,100, despite no significant change in overall antimicrobial use. Usage shifted to agents with longer half-lives, thereby terms of time to receipt of an appropriate antibiotic (table 7) . For nosocomial infections, a trend toward a shorter time to resulting in fewer total doses given (from 31,734 doses in 1993 to 30,038 doses in 1994; P Å .08). Thus, there may have receipt of an appropriate antibiotic during the period of restrictions was noted for both fatal and nonfatal cases. For commubeen additional savings in administration costs (e.g., minibags, tubing, etc.). The effects of restrictions on antibiotic usage and nity-acquired infection, the median time to receipt of an appropriate antibiotic was £3 hours during both years. pharmacy expenditures were similar to those described by other researchers [3, 6, 8, 9, 11 -13] . We noted an overall decrease For survivors, the median length of hospital stay from the first positive blood culture to discharge was 12 days during in use of parenteral antifungal drugs, but this decrease was in part due to increased use of oral instead of parenteral fluconaboth periods (table 8). Significant risk factors for increased length of hospital stay according to multiple logistic regression zole. Other potential benefits from using narrower-spectrum agents (e.g., changes in antibiotic-related adverse events such were nosocomial acquisition of bacteremia, increased modified SAPS II, and admission to the surgical service. No significant as Clostridium difficile colitis) were not monitored. differences in duration of ICU stay were noted between the Resistance to antimicrobial agents also decreased. During two study periods.
this period, there was a change in the NCCLS guidelines for reporting susceptibility data, and the effect of this change may have led to our underestimating the impact on susceptibility Discussion patterns. Isolates were stratified by site of collection, and duplicate specimens from an individual patient were eliminated. These data show that requiring prior authorization for use Thus, the decreased resistance is not likely due to reporting of selected antimicrobials resulted in a dramatic shift in antimicrobial usage from expensive, broad-spectrum agents to less bias. There was a dose-response relationship between increased / 9c38$$au41 07-21-97 13:46:40 cida UC: CID susceptibilities and exposure to restricted agents, with dramatic charged patients. Increased susceptibilities to both restricted and unrestricted antibiotics were noted. increased susceptibilities in isolates recovered in ICUs (where usage of restricted antibiotics was greatest) and minimal change
We do not know the reason for increased susceptibilities to unrestricted agents such as ceftriaxone. The pattern of resisin susceptibilities in isolates recovered in outpatient sites. The slight increased susceptibilities in isolates from outpatients may tance to a number of b-lactam antibiotics by several genera of organisms is consistent with a high prevalence of broad-spechave resulted from inclusion of isolates from recently dis- Table 5 . Thirty-day survival by organism among patients with bacteremia due to gram-negative bacilli during the 6-month period before (July -December 1993) and after (July -December 1994) full implementation of the prior-authorization requirement for antimicrobials. Table 6 . Risk factors for decreased survival in patients with bacteremia due to gram-negative bacilli during the 6-month period before (July -December 1993) and after (July -December 1994) implementation of the prior-authorization requirement according to multiple logistic regression. Another hypothesis for the reduction in resistance is that Subtotal 24 12 restricted use of certain broad-spectrum agents such as ceftazi-NOTE. There were no statistically significant differences between groups.
dime may have decreased the selection effect on broad-spec-/ 9c38$$au41 07-21-97 13:46:40 cida UC: CID [31] , however, infections before the onset of bacteremia. We detected 14 fewer nosocomial bloodstream infections in the 6-month period in documented a dramatic decrease in the prevalence of ceftazidime-resistant Klebsiella in spite of unchanged infection con-1994. By the first 6 months of 1995, the number of cases of nosocomial bacteremia had decreased to 44 compared with 74 trol practices when piperacillin/tazobactam was added to the formulary and promoted as an alternative to ceftazidime.
in the 6 months before implementation of the restriction. The decreased expenditures for management of nosocomial bacterThe shift in the antimicrobial agents used most may have decreased the overall selection effect of antibiotics on resistant emia may have been greater than the entire decrease in antibiotic acquisition costs [35] . For example, Pittet and colleagues organisms. The switch to antibiotics with longer biological half-lives along with a decrease in the total grams of antibiotics [35] documented excess clinical expenditures of $40,000 per episode for patients with nosocomial bacteremia compared with used may also have decreased the selection effect. The frequency of the selection effect of antibiotics on resistant organmatched patients without bacteremia. Survival rates among patients with bacteremia due to gramisms varies [32] . Some investigators have suggested that use of ceftazidime is more strongly associated with resistance than negative bacilli were virtually identical during both years, with no significant changes in outcomes for any subgroup. A statistiis use of other b-lactam agents [21 -23] . Thus, the marked decrease in ceftazidime use at our hospital may be the principal cally insignificant trend toward lower survival rates among patients with nosocomial bacteremia was noted, but this trend cause for decreased resistance. Other researchers have noted no change [8] or even decreased susceptibilities to antibiotics did not persist despite continuation of the prior-authorization requirement. Furthermore, a substantial number of the patients [12] with similar antibiotic control programs, but these other programs were instituted before the widespread use of ceftaziwho died during the study period were receiving appropriate antibiotics at the time that the positive blood cultures were dime. Pestotnik and colleagues [33] recently described a computer-assisted antibiotic management program that significantly obtained. Bacteremia during antibiotic therapy is a risk factor for poor outcome regardless of treatment [36] . Thus, host facdecreased antibiotic use. No major effect on antimicrobial susceptibility was noted, perhaps because of a low prevalence tors may have played a larger role in the case-fatality rate than did initial antibiotic choice. of resistance. It is interesting that trends suggested improved susceptibilities in Pseudomonas and Enterobacter isolates to Hirschman and colleagues [8] noted no change in the overall survival rate among patients with bacteremia when antibiotics both ceftazidime, which was used significantly less, and imipenem, which was used more.
were restricted, but data comparing the patient groups were not assessed. Other groups of investigators have noted no sigThe decreased prevalence of resistance may also have resulted from more appropriate use of antimicrobials. We did nificant difference in the mortality rate or length of stay for patients hospitalized after initiation of antibiotic control pronot obtain any direct measures of appropriateness of antimicrobial use. However, we did provide improved access to the grams [11, 13] . Since these analyses included all hospitalized patients, any benefit for or adverse effects on the subgroup infectious diseases faculty, who were available 24 hours a day.
/ 9c38$$au41
07-21-97 13:46:40 cida UC: CID with severe infections may not have been detected or may have controlled but only which controls are optimal for a particular health care system. been masked by changes in case-mix.
Analysis of survival by organism showed no significant differences between the 2 years. A trend was noted toward
